FOLH1 and prostate carcinoma: Prostate cancer is suitable for vaccine therapy because it has many TAAs such as PSA, prostate-specific membrane antigen (PSMA), prostate acid phosphatase (PAP), prostate stem cell antigen (PSCA), prostate cancer antigen 3 (PCA3), mucin-1, and six-transmembrane epithelial antigens of the prostate (STEAP)[58].